Protein behind immunity to ovarian cancer treatment identifiedDecember 17th, 2007 - 1:17 pm ICT by admin
London, Dec 17 (ANI): People suffering from ovarian cancer who have lower levels of protein called TGFBI, are less likely to respond to the treatment for cancer, says a study.
Transforming growth factor, beta-induced, 68kDa, also known as TGFBI, is a human gene.
The finding was based on a study, led by Dr James Brenton, a Cambridge University researcher, which found that patients lacking the protein tend to be immune to Paclitaxel, a drug that shrinks ovarian tumours.
Paclitaxel is part of a family of drugs called taxanes, originally derived from yew trees.
In the study, the researchers examined ovarian cancer cells and data from 20 patients.
They results found that those who did not respond to paclitaxel had lower levels of a protein called TGFBI in their pre-treatment samples.
And further analysis revealed that cancer cell death rate was higher following treatment where levels of TGFBI were high.
“TGFBI is lost in one third of primary ovarian cancers and it is possible that this protein could be used as a biomarker for selecting patients likely to respond to this class of drug, BBC quoted Brenton, as saying.
“Our findings offer hope not only for improved ovarian cancer treatment, it may also lead to improvements in the success rate of other taxane drugs used to treat lung and breast cancer, he added.
Dr Ahmed Ashour Ahmed, who also worked on the study, said: “Our work reveals that some proteins that surround cancer cells such as TGFBI send messages to microtubules, the backbone of the cell, sensitising them to paclitaxel.
“Deciphering the code by which these messages are sent will enable the discovery of new treatments that will simulate the coded messages leading to a significant improvement in paclitaxel response, he added.
Professor Herbie Newell, of Cancer Research UK, said: “We are entering a period of cancer treatment where more drugs are targeted at those people who will benefit the most.
“This personalised medicine approach potentially means treatments will be more effective with fewer side effects. This is really important for diseases like ovarian cancer that can be challenging to treat, Newell added. (ANI)
- Potential new target for treatment of ovarian cancer identified - Aug 17, 2010
- Motor protein that blocks ovarian tumor growth found - Apr 27, 2011
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Novel study offers hope for new class of Alzheimer's drugs - Oct 19, 2010
- Critical 'traffic engineer' of the nervous system found - Sep 09, 2010
- Gene makes ovarian cancer resistant to chemotherapy - Mar 03, 2011
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- Plant stem cells pave way for low-cost cancer drug - Oct 26, 2010
- Nanostars harnessed to target cancer core - Apr 09, 2012
- New discovery may help overcome taxane resistance in cancer - Jan 27, 2010
- Trio of drugs may help fight 'triple negative' breast cancer - Dec 11, 2010
- Study suggests another avenue for detecting Alzheimer's - Apr 02, 2011
- New drug shows promise against ovarian and breast cancer - Aug 13, 2010
Tags: ashour, biomarker, breast cancer, brenton, cambridge university, cancer cell, cancer cells, cancer research uk, cancer treatment, cell death, death rate, dr ahmed, growth factor beta, human gene, ovarian cancer, ovarian cancers, ovarian tumours, paclitaxel, university researcher, yew trees